Procaps Group and Genomma Lab Internacional, S.A.B. de C.V. announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.775 USD | +5.92% | +0.91% | -31.82% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.67 MXN | +2.27% | +8.60% | 911M | ||
2.775 USD | +5.92% | +0.91% | 296M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.82% | 296M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- PROC Stock
- News Procaps Group S.A.
- Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America